Delivery Order SPE2DR25D1100-SPE2DR26FCM4R
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Cryselle-28 tablets (28-count packaging) on October 22, 2025, with a ceiling value of $1,089.41 and completion targeted for October 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $2,624.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for Cryselle-28 tablets (28-count packages) on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitively awarded contract, with no set-aside designation, is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,702.12, is for the delivery of CRYSELLE-28 TABLET 28S medical supplies. The contract has an ultimate completion date of February 13, 2025 and is a firm fixed-price contract type. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA...
- This delivery order, valued at $2,023.19, was awarded to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Cryselle 0.3-0.03 contraceptive medication. The contract is non-competitive and represents a child order under a larger Indefinite Delivery Contract vehicle with the Defense Logistics Agency Troop Support Medical. Performance will occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 26, 2025. This award was...
- The Defense Logistics Agency awarded a delivery order valued at $45,474.95 to AmerisourceBergen Drug Corp on October 30, 2025, for pharmaceutical products and medical supplies under a firm fixed price contract. This non-competitive delivery order, with an ultimate completion date of October 31, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- This delivery order, awarded on October 20, 2025, is for Yasmin 28 Tablet contraceptive medication with a ceiling value of $1,129.38. The Defense Logistics Agency (DLA) awarded this firm fixed-price, non-set-aside contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The place of performance is also located in Conshohocken, PA, and the delivery order is scheduled for completion by October 21, 2025. This award is issued as a child...
- The U.S. Defense Logistics Agency's Medical Supply Chain has awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies valued at $5,163.14. The contract, designated as a firm fixed price delivery order without set-aside provisions, is scheduled for completion by July 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The specific product being...
- The Defense Logistics Agency awarded a delivery order valued at $15,967.36 to AmerisourceBergen Drug Corp on November 4, 2025, with an ultimate completion date of November 5, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order calls for pharmaceutical products and medical supplies to support federal healthcare operations,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,561.20 to AmerisourceBergen Drug Corp on September 13, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract for pharmaceutical and medical supply products. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $14,465.28 to AmerisourceBergen Drug Corp on November 3, 2025, with completion expected by November 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor for medical supply fulfillment. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and supplies a...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCM4RDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,941.91 to AmerisourceBergen Drug Corp for Cryselle-28 tablets on November 4, 2025, with completion scheduled for November 5, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitively awarded pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the DLA's medical supply chain, delivering a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables global pharmaceutical support for military healthcare programs worldwide. The contract vehicle encompasses specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The DLA has positioned this contract as part of its Pharmaceutical Prime Vendor Global Program Generation V initiative, which is structured to make multiple awards across separate regions with different contractors, demonstrating the strategic importance of diversified pharmaceutical sourcing for federal medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 11/4/25 |